A Metabonomics Approach to Drug Toxicology in Liver Disease and its Application in Traditional Chinese Medicine-Reference-Cited by-同舟云学术

A Metabonomics Approach to Drug Toxicology in Liver Disease and its Application in Traditional Chinese Medicine

Published:2019-06-11 Issue:4 Volume:20 Page:292-300
ISSN:1389-2002
Container-title:Current Drug Metabolism
language:en
Short-container-title:CDM

Author:

Su Guangyue¹,Wang Haifeng²,Bai Jiao²,Chen Gang²,Pei Yuehu²

Affiliation:

1. School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China

2. Department of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China

Abstract

Background: The progression of liver disease causes metabolic transformation in vivo and thus affects corresponding endogenous small molecular compounds. Metabonomics is a powerful technology which is able to assess global low-molecular-weight endogenous metabolites in a biological system. This review is intended to provide an overview of a metabonomics approach to the drug toxicology of diseases of the liver. Methods: The regulation of, and relationship between, endogenous metabolites and diseases of the liver is discussed in detail. Furthermore, the metabolic pathways involved in drug interventions of liver diseases are reviewed. Evaluation of the protective mechanisms of traditional Chinese medicine in liver diseases using metabonomics is also reviewed. Examples of applications of metabolite profiling concerning biomarker discovery are highlighted. In addition, new developments and future prospects are described. Results: Metabonomics can measure changes in metabolism relating to different stages of liver disease, so metabolic differences can provide a basis for the diagnosis, treatment and prognosis of various diseases. Conclusion: Metabonomics has great advantages in all aspects of the therapy of liver diseases, with good prospects for clinical application.

Funder

National Natural Science Foundation of China

Science and Technology Department of Guangxi Province

Publisher

Bentham Science Publishers Ltd.

Subject

Clinical Biochemistry,Pharmacology

Reference87 articles.

1. Luo W-J, Cheng T-Y, Wong K-I, Fang W-h, Liao K-M, Hsieh Y-T, Su K-Y. Novel therapeutic drug identification and gene correlation for fatty liver disease using high-content screening: Proof of concept.

2. Attia MS, Youssef AO, Khan ZA, Abou-Omar MN. Alpha fetoprotein assessment by using a nano optical sensor thin film binuclear Pt-2-aminobenzimidazole-Bipyridine for early diagnosis of liver cancer.

3. Hong SK, Yi N-J, Chang H, Ahn S-W, Kim H-S, Yoon KC, Kim H, Park SO, Jin US, Minn KW, Lee K-W, Suh K-S. The rate of hepatic artery complications is higher in pediatric liver transplant recipients with metabolic liver diseases than with biliary atresia.

4. Zhu C, Liang Q-L, Wang Y-M, Luo G-A. Integrated development of metabonomics and its new progress.

5. Colet J-M. Metabonomics in the preclinical and environmental toxicity field.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the potential mechanism and therapeutic effects of SLXG for cholesterol gallstone treatment;Phytomedicine;2024-09

2. Integrating metabolomics and bioinformatics to reveal the mechanism of Epimedium‐induced liver injury;Biomedical Chromatography;2024-07-09

3. Assessment of progression of pulmonary fibrosis based on metabonomics and analysis of intestinal microbiota;Artificial Cells, Nanomedicine, and Biotechnology;2024-03-15

4. Metabolomics analysis delineates the therapeutic effects of Yinlan Tiaozhi capsule on triton WR-1339 -induced hyperlipidemia in mice;Frontiers in Pharmacology;2023-10-30

5. Characterization of chemical constituents and metabolites in vivo and in vitro after oral administration of Wuteng tablets in rats by UHPLC–Q/TOF–MS;Biomedical Chromatography;2023-07-26